LLY ELI LILLY & Co (LLY) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000059478
Congress · 4Form 144 · 5
Insider buyers, 180 days
0
Funds added, last quarter
2,626
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
What the filings say about LLY
Insiders, 180 days
-$34.6M net sold
5 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
4 bought · 6 sold
Latest: sale, 2026-07-10
Planned sales (Form 144), 90 days
$737.8M
5 notices
ELI LILLY & Co insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ELI LILLY & Co insiders sold a net $34.6M of stock across 1,147 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 1, 2023.
- The trade is 12.0% of the 54,146 shares held after it.
- 2 other insiders sold within 30 days.
- 2,626 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & President, LLY Int'l Jonsson Patrik sold about $7.6M of LLY on Aug 17, 2026; 2 other insiders sold within 30 days and 2,626 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Nov 13, 2025.
- The trade is 131.1% of the 1,525 shares held after it.
- 2 other insiders sold within 30 days.
- 2,626 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Finance, & CAO Zakrowski Donald A sold about $2.4M of LLY on Aug 10, 2026; 2 other insiders sold within 30 days and 2,626 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 42.1% of the 11,875 shares held after it.
- 2 other insiders sold within 30 days.
- 2,626 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC & Secretary Hakim Anat sold about $6.0M of LLY on Aug 7, 2026; 2 other insiders sold within 30 days and 2,626 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 11, 2025.
- The trade is 8.4% of the 29,804 shares held after it.
- No other insider sold within 30 days.
- 2,626 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP&Pres, LLY USA&Global Capab Yuffa Ilya sold about $2.9M of LLY on Jun 10, 2026; 2,626 funds added in the latest 13F quarter.Context
- 1096 earlier Form 4 trades (code P or S) here by this insider (1096 sales), the last on Jan 7, 2026.
- The trade is 0.0% of the 91,881,150 shares held after it.
- No other insider sold within 30 days.
- 2,626 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider LILLY ENDOWMENT INC sold about $2.2M of LLY on May 6, 2026; 2,626 funds added in the latest 13F quarter.1,147 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$34.6M over 180 days
-$16.0M over 90 days
below 92% of Pharma & Biotech
Congress
4 members bought in the last year
the highest in Pharma & Biotech
Funds
2,626 funds bought in last quarter
the highest in Pharma & Biotech
Revenue
+44.7% year over year
more than 75% of Pharma & Biotech
Margin
31.7% net margin
more than 91% of Pharma & Biotech
Buybacks
$4.0B repurchased, FY to 2026-06-30
more than 99% of Pharma & Biotech
Short interest
0.8% of the float short (float per yahoo 2026-10-26) · 2.9 days to cover · settled 2026-09-30
below 76% of Pharma & Biotech
What changed in the last 30 days
Oct 15Shareholder LILLY ENDOWMENT, INC. filed to sell $368.7M by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 7Shareholder LILLY ENDOWMENT, INC. filed to sell $347.2M by Oct 7 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch LLY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+57.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LLY: institutional holders (13F)
13F holdings, latest reported quarter
90,376,978 sh
$108.4B
67,540,400 sh
$81.0B
53,528,868 sh
$64.2B
51,322,720 sh
$61.6B
36,215,754 sh
$43.4B
Congress trades in LLY
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-07-10 · disclosed 7 days later
$1,001 - $15,000
Sold 2026-07-01 · disclosed 37 days later
$1,001 - $15,000
Bought 2026-06-10 · disclosed 22 days later
$50,001 - $100,000
Bought 2026-04-14 · disclosed 24 days later
$1,001 - $15,000
Sold 2026-04-08 · disclosed 23 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LLY planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
LILLY ENDOWMENT, INC.
Filed 2026-10-15
$368.7M
LILLY ENDOWMENT, INC.
Filed 2026-10-07
$347.2M
Patrik Jonsson
Filed 2026-08-17
$7.6M
DONALD ZAKROWSKI
Filed 2026-08-10
$2.4M
Hakim Anat
Filed 2026-08-07
$11.9M
LLY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Pharmaceuticals Portfolio
$431.8M position · as of 2026-05-31
28.8%
iShares U.S. Pharmaceuticals ETF
$253.2M position · as of 2026-06-30
22.2%
Harbor Health Care ETF
$8.6M position · as of 2026-07-31
20.8%
VanEck Pharmaceutical ETF
$177.9M position · as of 2026-06-30
20.2%
Horizon Kinetics Medical ETF
$3.5M position · as of 2026-06-30
18.5%
PGIM Jennison Health Sciences Fund
$240.9M position · as of 2026-05-29
17.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Ricks
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$36.7M
$75.2M
$10.9M
+571%
+54%
2024
$29.2M
$80.6M
$6.1M
+378%
+23%
2023
$26.6M
$120.9M
$7.8M
+259%
+18%
2022
$21.4M
$64.1M
$5.8M
+123%
+25%
2021
$21.5M
$75.7M
$4.7M
+66%
+17%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $34.6M sold by insiders over 180 days, 2,626 funds added last quarter, 4 House member(s) bought in 12 months, disclosed weeks after the trade, $737.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
LLY financials
Revenue growth
+44.7%
XBRL, annual
Net margin
31.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$79.7B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LLY
| FY Dec 2025 | $65.2B |
| FY Dec 2024 | $45.0B |
| FY Dec 2023 | $34.1B |
| FY Dec 2022 | $28.5B |
| FY Dec 2021 | $28.3B |
| Jun 2026 | $23.0B |
| Mar 2026 | $19.8B |
| Dec 2025 | $19.3B |
| Sep 2025 | $17.6B |
| Jun 2025 | $15.6B |
| Mar 2025 | $12.7B |
| Dec 2024 | $13.5B |
| Sep 2024 | $11.4B |
At each fiscal year end
Single quarter
Net margin, TTM
+33.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LLY
| FY Dec 2025 | +31.7% |
| FY Dec 2024 | +23.5% |
| FY Dec 2023 | +15.4% |
| FY Dec 2022 | +21.9% |
| FY Dec 2021 | +19.7% |
| Jun 2026 | +30.9% |
| Mar 2026 | +37.4% |
| Dec 2025 | +34.4% |
| Sep 2025 | +31.7% |
| Jun 2025 | +36.4% |
| Mar 2025 | +21.7% |
| Dec 2024 | +32.6% |
| Sep 2024 | +8.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$18.2B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LLY
| FY Dec 2025 | $9.0B |
| FY Dec 2024 | $3.8B |
| FY Dec 2023 | $792.0M |
| FY Dec 2022 | $5.7B |
| FY Dec 2021 | $6.1B |
| Jun 2026 | $7.8B |
| Mar 2026 | $3.0B |
| Dec 2025 | $677.9M |
| Sep 2025 | $6.7B |
| Jun 2025 | $1.4B |
| Mar 2025 | $156.0M |
| Dec 2024 | $977.7M |
| Sep 2024 | $2.4B |
At each fiscal year end
Single quarter
Debt to equity
1.62x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity LLY
| FY Dec 2025 | 1.60x |
| FY Dec 2024 | 2.36x |
| FY Dec 2023 | 2.34x |
| FY Dec 2022 | 1.52x |
| FY Dec 2021 | 1.88x |
| Jun 2026 | 1.62x |
| Mar 2026 | 1.39x |
| Dec 2025 | 1.60x |
| Sep 2025 | 1.79x |
| Jun 2025 | 2.18x |
| Mar 2025 | 2.44x |
| Dec 2024 | 2.36x |
| Sep 2024 | 2.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.51x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt LLY
| FY Dec 2025 | 0.40x |
| FY Dec 2024 | 0.26x |
| FY Dec 2023 | 0.17x |
| FY Dec 2022 | 0.47x |
| FY Dec 2021 | 0.44x |
| Jun 2026 | 0.51x |
| Mar 2026 | 0.47x |
| Dec 2025 | 0.40x |
| Sep 2025 | 0.38x |
| Jun 2025 | 0.27x |
| Mar 2025 | 0.24x |
| Dec 2024 | 0.26x |
| Sep 2024 | 0.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+102.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LLY
| FY Dec 2025 | +101.2% |
| FY Dec 2024 | +84.6% |
| FY Dec 2023 | +48.9% |
| FY Dec 2022 | +63.6% |
| FY Dec 2021 | +76.4% |
| Jun 2026 | +102.4% |
| Mar 2026 | +107.6% |
| Dec 2025 | +101.2% |
| Sep 2025 | +96.8% |
| Jun 2025 | +86.7% |
| Mar 2025 | +77.7% |
| Dec 2024 | +84.6% |
| Sep 2024 | +65.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+22.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LLY
| FY Dec 2025 | +21.6% |
| FY Dec 2024 | +14.8% |
| FY Dec 2023 | +9.2% |
| FY Dec 2022 | +12.7% |
| FY Dec 2021 | +11.7% |
| Jun 2026 | +22.0% |
| Mar 2026 | +24.5% |
| Dec 2025 | +21.6% |
| Sep 2025 | +19.3% |
| Jun 2025 | +16.0% |
| Mar 2025 | +14.5% |
| Dec 2024 | +14.8% |
| Sep 2024 | +12.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital LLY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed LLY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
42.73x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing LLY
| FY Dec 2025 | 46.83x |
| FY Dec 2024 | 65.93x |
| FY Dec 2023 | 100.50x |
| FY Dec 2022 | 53.02x |
| FY Dec 2021 | 45.06x |
| Jun 2026 | 40.25x |
| Mar 2026 | 32.67x |
| Dec 2025 | 46.83x |
| Sep 2025 | 37.33x |
| Jun 2025 | 50.95x |
| Mar 2025 | 67.20x |
| Dec 2024 | 65.93x |
| Sep 2024 | 95.78x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.2T
market value at close 2026-10-23 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value LLY
| FY Dec 2025 | $1.1T |
| FY Dec 2024 | $763.2B |
| FY Dec 2023 | $575.8B |
| FY Dec 2022 | $361.8B |
| FY Dec 2021 | $277.3B |
| Jun 2026 | $1.2T |
| Mar 2026 | $905.8B |
| Dec 2025 | $1.1T |
| Sep 2025 | $754.9B |
| Jun 2025 | $775.3B |
| Mar 2025 | $818.5B |
| Dec 2024 | $763.2B |
| Sep 2024 | $869.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.5%
TTM free cash flow over market value at close 2026-10-23
FCF yield LLY
| FY Dec 2025 | +0.9% |
| FY Dec 2024 | +0.5% |
| FY Dec 2023 | +0.1% |
| FY Dec 2022 | +1.6% |
| FY Dec 2021 | +2.3% |
| Jun 2026 | +1.6% |
| Mar 2026 | +1.4% |
| Dec 2025 | +0.9% |
| Sep 2025 | +1.3% |
| Jun 2025 | +0.7% |
| Mar 2025 | +0.5% |
| Dec 2024 | +0.5% |
| Sep 2024 | +0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.45x
P/E over trailing EPS growth of 95%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing LLY
| FY Dec 2025 | 0.49x |
| FY Dec 2024 | 0.65x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 4.22x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.42x |
| Mar 2026 | 0.25x |
| Dec 2025 | 0.49x |
| Sep 2025 | 0.31x |
| Jun 2025 | 0.58x |
| Mar 2025 | 0.83x |
| Dec 2024 | 0.65x |
| Sep 2024 | 1.42x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $65.2B | $45.0B | $34.1B | $28.5B |
| Net income | $20.6B | $10.6B | $5.2B | $6.2B |
| EPS (diluted) | 22.95 | 11.71 | 5.80 | 6.90 |
| Operating cash flow | $16.8B | $8.8B | $4.2B | $7.6B |
| Cash | $7.3B | $3.3B | $2.8B | $2.1B |
| Long-term debt | $40.9B | $28.5B | $18.3B | $14.7B |
| Buybacks | $4.1B | $2.5B | $750.0M | $1.5B |
| Dividends paid | $5.4B | $4.7B | $4.1B | $3.5B |
SEC XBRL, fiscal years, as known on 2026-10-27
LLY Stock Sonar score 6/7 axes
Find similar shapesCompareLLY ranks highest on profitability (95th percentile) and growth (75th), and lowest on insider conviction (3rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LLY filings, in plain words
Are ELI LILLY & Co insiders buying or selling LLY?
In the 180 days to 2026-10-27, ELI LILLY & Co insiders were net sellers, a net $34.6M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded LLY?
Yes. In the year to 2026-10-27, 4 House members disclosed buying LLY and 6 House members disclosed selling it; the latest on record is a sale by Dan Newhouse dated 2026-07-10.
Are there planned insider sales of LLY?
Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $737.8M of stock; the latest, by LILLY ENDOWMENT, INC., was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-27, ELI LILLY & Co insiders were net sellers of LLY, a net $34.6M across purchases and sales reported on Form 4 by 5 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 4 members of Congress disclosed buying LLY and 6 members disclosed selling it; the latest on record is a sale by Dan Newhouse dated 2026-07-10. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $737.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
